Navigation Links
Self-moisturizing contact lenses, naturally
Date:7/8/2008

Even contact lenses are joining the trend to go green.

Chemical engineering researchers at McMaster University have shown that a common fluid found in our bodies can be used as a natural moisturizing agent in contact lenses.

This is a step up from the current wave of self-moisturizing contact lenses that use synthetic materials as a wetting agent to prevent eye dryness and increase wearer comfort.

It is estimated that more than 50 per cent of people who stop wearing contact lenses do so because of discomfort caused by dryness, which is particularly high at the end of the day.

The research from McMaster, recently published in the journal Biomaterials, showed that hyaluronic acid can be entrapped in existing contact lens material without affecting optical properties.

It was also found that using hyaluronic acid considerably reduces the build up of proteins which can cloudy contact lens material, the cause of up to 30 per cent of all after-care visits by contact lens wearers to optometrists. [That's one less appointment and one more step towards reducing your carbon footprint.]

Hyaluronic acid is a natural polymer that acts to reduce friction. An average person weighing 70-kg has about 15 grams of hyaluronic acid in their body, one third of which is turned over daily. The body uses hyaluronic acid to repair skin, provide resiliency in cartilage, and contribute to the growth and movement of cells, among other things. It is also used by the medical profession to treat patients with dry eyes, in cataract surgery, and for other eye-related procedures.

While manufacturers have not yet produced contact lenses with hyaluronic acid, the researchers remain hopeful.

"We've shown that the process works," said Heather Sheardown, professor of chemical engineering at McMaster and a member of the McMaster School of Biomedical Engineering, who was involved in the research. "We're optimistic tha
'/>"/>

Contact: Gene Nakonechny
genen@mcmaster.ca
905-525-9140 x26781
McMaster University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Its all about geometry: Protein contact surfaces hold key to cures
2. Naturally-occurring apple compounds reduce risk of pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... of researchers, including scientists from the Max Planck Institute ... a major step in understanding photosynthesis, the process by ... oxygen in its atmosphere and which is therefore crucial ... , The researchers report the first direct visualization of ... step in which a specific protein complex, photosystem II, ...
(Date:7/11/2014)... Recent evidence has demonstrated that transplantation of mesenchymal stem ... rat or mouse models of Alzheimer,s disease (AD) and ... cerebral ischemia. Few studies are reported on the therapeutic ... with AD and on the effect on oxidative injury ... Yufang Yan and her team, School of Life Sciences, ...
(Date:7/11/2014)... Research and Markets has announced the addition ... Analysis Size Share Growth Trends and Forecast to 2019" ... http://photos.prnewswire.com/prnh/20130307/600769 The rising number of ... high level security in both private and public sector. ... and passwords, tokens etc. are vulnerable to attacks. Biometrics ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... Listeria monocytogenes invades the body, it commandeers its host ... report published in the Journal of Biological Chemistry, a ... behind this infection technique. , The research appears as ... issue of the Journal of Biological Chemistry, an American ...
... analysis published in the Feb. 8 PNAS supports the ... , Researchers in California, Israel, and Germany have compared ... the fruit fly ?and reported that protein "wiring" connections ... This first-of-its-kind analysis of three higher level organisms published ...
... Bioengineering and Nanotechnology (IBN) has developed a novel method ... which can be used in pharmaceutical synthesis and novel ... in the leading Chemistry journal, Angewandte Chemie, and a ... , Research Scientist Dr. Yu Han and IBN Executive ...
Cached Biology News:Scientists discover that host cell lipids facilitate bacterial movement 2Examination of internal 'wiring' of yeast, worm, and fly reveals conserved circuits 2Examination of internal 'wiring' of yeast, worm, and fly reveals conserved circuits 3Examination of internal 'wiring' of yeast, worm, and fly reveals conserved circuits 4Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications 2
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... in part) in, into or from any jurisdiction where to ... of such jurisdiction.  Shire plc ("Shire" or the ... Bloomberg article this afternoon.  Shire confirms it has held a ... being made by Shire without the prior agreement or approval ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... Israel and JERSEY CITY, New Jersey, December 5, Rosetta ... the,development of microRNA-based diagnostics and therapeutics, announced today,that it ... on,Thursday, December 10, from 2:30-3:35 pm EST at the ... A live audio webcast of the ...
... developing solutions based on the products of newborn fibroblasts, will be ... of the 21st Century Breakthroughs for Biomedical Research series. , ... ... a regenerative medicine company developing solutions based on the products of ...
... (Nasdaq: BCRX ) announced today that the Company ... clinical data on BCX-4208 at the 50th American Society of ... Francisco, CA from December 6-9, 2008. Forodesine HCl and ... , The schedule for BioCryst,s poster ...
Cached Biology Technology:Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference 2Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference 3Histogen Featured on Economic Report Television Series 2BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition 2BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition 3